Individualized treatment with denosumab in children with osteogenesis imperfecta – follow up of a tr...
Individualized treatment with denosumab in children with osteogenesis imperfecta – follow up of a trial cohort
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Osteogenesis imperfecta (OI) is a rare disease leading to hereditary bone fragility. Nearly 90% of cases are caused by mutations in the collagen genes COL1A1/A2 (classical OI) leading to multiple fractures, scoliosis, short stature and nonskeletal findings as blue sclera, hypermobility of joints, bone pain and delayed motor function development. Bi...
Alternative Titles
Full title
Individualized treatment with denosumab in children with osteogenesis imperfecta – follow up of a trial cohort
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b74ec028ed794c5497ac0e67945fbc90
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b74ec028ed794c5497ac0e67945fbc90
Other Identifiers
ISSN
1750-1172
E-ISSN
1750-1172
DOI
10.1186/s13023-019-1197-z
